news
Synthetic antibody treats congenital myasthenia in mice
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
List view / Grid view
Biologics
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
whitepaper
Product hub: Octet® R series systems
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
article
Using cholangiocyte organoids to regenerate human bile ducts
A team of researchers has shown that injection of cholangiocyte organoids in human livers ex vivo can repair the organs’ bile ducts. In this article, Dr Fotios Sampaziotis explains how his team’s study provides the first proof-of-principle for the efficacy of cellular therapies using organoids in human.
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
article
Drug Target Review – Issue 2 2021
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
news
Very long-chain fatty acids found to block SARS-CoV-2 infection
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
article
Challenges and opportunities in gene therapy development
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
news
New synthetic biologic could treat obesity-related diseases
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
news
Nanobody cocktail shown to block SARS-CoV-2 infection in mouse models
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
article
Which CHO cell is the right CHO cell?
Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.
whitepaper
Product hub: The world’s first BioPharma Lifecycle Management system – navigating your biopharma lifecycle
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.
news
Method for analysing sugar-protein interactions could enable better biologics
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.